The Department of Health and Social Care (DHSC) has issued updated advice on current hormone replacement therapy (HRT) shortages which shows some problems are expected to continue well into next year.
It lists six products that are out of stock on a long-term basis and another three currently unavailable but with more supplies due soon.
The list, which was issued along with a prescribing advice guide, also shows that Evorel products are due to run out in September and October with no new stocks expected until the middle of 2020.
Related Article: Almost five million Pharmacy First consultations delivered in first year
The DHSC confirmed there were supply problems with a small number of oral contraceptive pills due to manufacturing delays but other types were available.
Unprecedented demand
Related Article: NPA 'decides against' collective action
Janssen-Cilag who make Evorel patches, which will start to run out next month, said they continued to face unprecedented demand in part because of a lack of availability of other HRT products and had already diverted stock to the UK from other countries with lower demand.
‘So far this year, demand in the UK has already exceeded that of the whole of 2018 depleting all surplus stock,’ a spokesperson said.
‘As a result, we are unfortunately anticipating a complete interruption to supply across the product range from October 2019, although certain patches may stock out earlier than this date. We are working on a return to full supply by mid-2020.’
Related Article: Government seeks pharmacists' views to underpin first-ever men’s health strategy
The NHS memo for prescribers advises following British Menopause Society guidance which states that ‘prescribers consider equivalent preparations that provide a similar dose to what their patient is using.’
But the recommendations also published on the Specialist Pharmacy Service website, conclude that: ‘If there is insufficient transdermal estradiol products to meet demand then prioritising their use for women at increased risk of [venous thromboembolism] may have to be considered.’
Have your say
Please add your comment in the box below. You can include links, but HTML is not permitted. Please note that comments are not moderated before publication and the views expressed are those of the user and do not reflect the views of The Pharmacist. Remember that submission of comments is governed by our Terms and Conditions. You can also read our full guidelines on article comments here – but please be aware that you are legally liable for any libellous or offensive comments that you make. If you have a complaint about a comment or are concerned that a comment breaches our terms and conditions, please use the ‘Report this comment’ function to alert our web team.